- 1 Supplementary Table S9. Summary of grade 3 or higher treatment-related adverse events
- 2 (TRAEs) of patients with advanced solid tumors treated with botensilimab monotherapy or
- 3 botensilimab in combination with balstilimab.

Treatment-related adverse events (TRAE), Grade 3 or higher	Botensilimab monotherapy (N=64)	Botensilimab + Balstilimab (N=147)	All Patients (N=211)
	Patients n (%)		
Colitis	7 (10.9)	15 (10.2)	22 (10.4)
Diarrhea	3 (4.7)	13 (8.8)	16 (7.6)
Fatigue	2 (3.1)	4 (2.7)	6 (2.8)
Lymphocyte Count Decreased	0	4 (2.7)	4 (1.9)
Nausea	0	4 (2.7)	4 (1.9)
Alanine Aminotransferase Increased	0	3 (2.0)	3 (1.4)
Aspartate Aminotransferase Increased	0	3 (2.0)	3 (1.4)
Pyrexia	0	3 (2.0)	3 (1.4)
Abdominal Pain	0	2 (1.4)	2 (0.9)
Acute Kidney Injury	0	2 (1.4)	2 (0.9)
Blood Alkaline Phosphatase Increased	0	2 (1.4)	2 (0.9)
Blood Creatine Phosphokinase Increased	0	2 (1.4)	2 (0.9)
Decreased Appetite	2 (3.1)	0	2 (0.9)
Enterocolitis	1 (1.6)	1 (0.7)	2 (0.9)
Hepatitis	0	2 (1.4)	2 (0.9)
Hypotension	2 (3.1)	0	2 (0.9)
Rash	1 (1.6)	1 (0.7)	2 (0.9)
Vomiting	0	2 (1.4)	2 (0.9)
Anemia	0	1 (0.7)	1 (0.5)
Arthralgia	0	1 (0.7)	1 (0.5)

Asthenia	1 (1.6)	0	1 (0.5)
Atrial Fibrillation	0	1 (0.7)	1 (0.5)
Back Pain	0	1 (0.7)	1 (0.5)
Dehydration	0	1 (0.7)	1 (0.5)
Eczema	1 (1.6)	0	1 (0.5)
Headache	0	1 (0.7)	1 (0.5)
Hypoalbuminemia	1 (1.6)	0	1 (0.5)
Hypophosphatasemia	0	1 (0.7)	1 (0.5)
Hypophysitis	0	1 (0.7)	1 (0.5)
Hypovolemic Shock	1 (1.6)	0	1 (0.5)
Immune-Mediated Hepatitis	0	1 (0.7)	1 (0.5)
Lower Gastrointestinal Hemorrhage	0	1 (0.7)	1 (0.5)
Lymphopenia	0	1 (0.7)	1 (0.5)
Malabsorption	1 (1.6)	0	1 (0.5)
Malaise	0	1 (0.7)	1 (0.5)
Myalgia	0	1 (0.7)	1 (0.5)
Neutropenia	0	1 (0.7)	1 (0.5)
Pneumonitis	0	1 (0.7)	1 (0.5)
Polyarthritis	0	1 (0.7)	1 (0.5)
Rash Maculo-Papular	0	1 (0.7)	1 (0.5)
Scleritis	0	1 (0.7)	1 (0.5)
Skin Ulcer	1 (1.6)	0	1 (0.5)
Stomatitis	1 (1.6)	0	1 (0.5)
Tumor Pain	1 (1.6)	0	1 (0.5)
	ad using Madiaal	Distignery for Drug	, Dogulatory Affaira

Adverse Events terms were coded using Medical Dictionary for Drug Regulatory Affairs (MedDRA) version 26.0. Patients with multiple events for a given preferred term were counted 4

5 only once. 6